A. P. Albino, D. M. Nanus, I. R. Mentle, C. Cordon-cardo, N. S. Mcnutt et al., Analysis of ras oncogenes in malignant melanoma and precursor lesions: correlation of point mutations with differentiation phenotype, Oncogene, vol.11, pp.1363-74, 1989.

H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-54, 2002.

J. H. Lee, J. W. Choi, and Y. S. Kim, Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis, Br J Dermatol, vol.164, pp.776-84, 2011.

K. Omholt, A. Platz, L. Kanter, U. Ringborg, and J. Hansson, NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression, Clin Cancer Res, vol.9, pp.6483-6491, 2003.

L. A. Akslen, S. Angelini, O. Straume, I. M. Bachmann, A. Molven et al., BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival, J Invest Dermatol, vol.125, pp.312-319, 2005.

G. V. Long, A. M. Menzies, A. M. Nagrial, L. E. Haydu, A. L. Hamilton et al., Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma, J Clin Oncol, vol.29, pp.1239-1285, 2011.

W. O. Greaves, S. Verma, K. P. Patel, M. A. Davies, B. A. Barkoh et al., Frequency and spectrum of BRAF mutations in a retrospective, singleinstitution study of 1112 cases of melanoma, J Mol Diagn, vol.15, pp.220-226, 2013.

H. Yang, B. Higgins, K. Kolinsky, K. Packman, Z. Go et al., RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models, Cancer Res, vol.70, pp.5518-5545, 2010.

K. T. Flaherty, I. Puzanov, K. B. Kim, A. Ribas, G. A. Mcarthur et al., Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med, vol.363, pp.809-828, 2010.

P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto et al., BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, pp.2507-2523, 2011.

J. A. Sosman, K. B. Kim, L. Schuchter, R. Gonzalez, A. C. Pavlick et al., Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib, N Engl J Med, vol.366, pp.707-721, 2012.

A. Hauschild, J. J. Grob, L. V. Demidov, T. Jouary, R. Gutzmer et al., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, vol.380, pp.358-65, 2012.

P. Lito, N. Rosen, and D. B. Solit, Tumor adaptation and resistance to RAF inhibitors, Nat Med, vol.19, pp.1401-1410, 2013.

C. Lebbé, A. How-kit, M. Battistella, A. Sadoux, M. P. Podgorniak et al., BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma, Melanoma Res, vol.24, pp.415-423, 2014.

C. Willmore-payne, J. A. Holden, S. Hirschowitz, and L. J. Layfield, BRAF and c-kit gene copy number in mutation-positive malignant melanoma, Hum Pathol, vol.37, pp.520-527, 2006.

P. I. Poulikakos, Y. Persaud, M. Janakiraman, X. Kong, C. Ng et al., RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E), Nature, vol.480, pp.387-90, 2011.

E. Colomba, Z. Hélias-rodzewicz, V. Deimling, A. Marin, C. Terrones et al., Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing, J Mol Diagn, vol.15, pp.94-100, 2013.

A. Didelot, L. Corre, D. Luscan, A. Cazes, A. Pallier et al., Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinicalformalin fixed paraffin embedded samples, Exp Mol Pathol, vol.92, pp.275-80, 2012.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)), Method Methods, vol.25, pp.402-410, 2001.

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1753, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

J. F. Emile, E. L. Diamond, Z. Hélias-rodzewicz, F. Cohen-aubart, C. F. Hyman et al., Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease, Blood, vol.124, pp.3016-3025, 2014.

S. Moreau, P. Saiag, P. Aegerter, D. Bosset, C. Longvert et al., Prognostic value of BRAFV600 mutations inmelanoma patients after resection of metastatic lymph nodes, Ann SurgOncol, vol.19, pp.4314-4335, 2012.

C. Marin, A. Beauchet, D. Capper, U. Zimmermann, C. Julié et al., Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility, Arch Pathol Lab Med, vol.138, pp.71-76, 2014.

M. H. Kim, J. S. Bae, D. J. Lim, H. Lee, S. R. Jeon et al., Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression, Endocr Relat Cancer, vol.21, pp.891-902, 2014.

C. Spittle, M. R. Ward, K. L. Nathanson, P. A. Gimotty, E. Rappaport et al., Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma, J Mol Diagn, vol.9, pp.464-71, 2007.

P. I. Poulikakos, C. Zhang, G. Bollag, K. M. Shokat, and N. Rosen, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, vol.464, pp.427-457, 2010.

J. N. Søndergaard, R. Nazarian, Q. Wang, D. Guo, T. Hsueh et al., Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032, J Transl Med, vol.8, p.39, 2010.

M. Yancovitz, A. Litterman, J. Yoon, E. Ng, R. L. Shapiro et al., Intra-and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma, PLoS One, vol.7, p.29336, 2012.

J. S. Wilmott, A. M. Menzies, L. E. Haydu, D. Capper, M. Preusser et al., BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma, Br J Cancer, vol.108, pp.924-955, 2013.

J. A. Curtin, J. Fridlyand, T. Kageshita, H. N. Patel, K. J. Busam et al., Distinct sets of genetic alterations in melanoma, N Engl J Med, vol.353, pp.2135-2182, 2005.

J. Greshock, K. Nathanson, A. Medina, M. R. Ward, M. Herlyn et al., Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines, Genes Chromosomes Cancer, vol.48, pp.419-447, 2009.

M. Stark and N. Hayward, Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays, Cancer Res, vol.67, pp.2632-2674, 2007.

G. Jönsson, C. Dahl, J. Staaf, T. Sandberg, P. O. Bendahl et al., Genomic profiling of malignant melanoma using tiling-resolution arrayCGH, Oncogene, vol.26, pp.4738-4786, 2007.

A. Gast, D. Scherer, B. Chen, S. Bloethner, S. Melchert et al., Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study, Genes Chromosomes Cancer, vol.49, pp.733-778, 2010.

J. L. Maldonado, J. Fridlyand, H. Patel, A. N. Jain, K. Busam et al., Determinants of BRAF mutations in primary melanomas, J Natl Cancer Inst, vol.95, pp.1878-90, 2003.

G. V. Long, J. S. Wilmott, D. Capper, M. Preusser, Y. E. Zhang et al., Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma, Am J Surg Pathol, vol.37, pp.61-66, 2013.

P. M. Pollock, U. L. Harper, K. S. Hansen, L. M. Yudt, M. Stark et al., High frequency of BRAF mutations in nevi, Nat Genet, vol.33, pp.19-20, 2003.

J. Bauer and B. C. Bastian, Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool, Dermatol Ther, vol.19, pp.40-49, 2006.